>> live from san francisco, welcome to bloomberg west where we cover invasion, technology and the future of business. here are some top bloomberg west stories making headlines this hour. apple is close to producing a new smart watch according to reports. the "wall street journal" reporting that multiple versions of the device will begin production in the next couple of months with an expected release later this fall. apple's new watch is said to include more than 10 centers to help track health and fitness. earlier this month, apple unveiled the new health kit to developers of the company's annual conference. amazon is temporarily burying the hatchet with a publisher.

the cite is reducing shipping times for j.c. rowling's new book. orders of the book could take an additional one to two days to ship compared to other titles. the two companies have been locked in a dispute over profit sharing from book sales causing amazon to stop selling many of the publishers nearly 5,000 titles. comedian chelsea handler is in deals to host a new show on netflix. she will begin a new show on netflix, the first of its kind. the frequency of shows has yet to be determined but opens the door for a larger variety of original content produced by netflix. handler's late-night program on the e network is scheduled to end this year. now to the lead story of the day, the time for apple's lon-awaited smart watch may be coming soon. they are working on multiple

versions of a watch that will incorporate several different screen sizes and more than 10 sensors to track things like health and fitness. earlier this month they showed you have a new app that could be put into the watch and says it's working with nike on health software. joining us is the head of technology of equity research at s & p capital. and our special guest host for the hour. you are a physician by training, you founded a couple of your own companies and were c.e.o. for a time and now an investor in many bio tech and health tech companies. so, this is the perfect story for you to discuss. i'm sure you've been following this, but how closely have you been following a potential iwatch from apple? >> very closely and i'm very, very excited about this. let's talk about it from a physician's point of view. 50% of all health care costs are due to lifestyle choices. why does that matter? well, 30% of americans are

obese. 50% don't get the proper amount of exercise. if you have more than one chronic disease, costs seven times more to take care of those patients. measure, reward, and you'll have good outcomes. we're thrilled about this. >> scott, what are you hearing from your sources in the supply chain, and elsewhere, about an iwatch, or whatever it's going to be called, and whether or not it's coming this year? >> well, look, this is something that we too are excited about. not only because we actually think that it's going to happen and it's going to happen this year, but also because time and time again it seems like this speculation about apple and a variety of offerings kind of manifest itself, and then nothing seems to materialize. so, we think that definitely before the holiday shopping season, apple's going to have at least an iwatch product in the market. but to be honest with you, emily, we're not so sure that

this is going to be a slam dunk product like a lot of folks expect. >> on that note, one third of consumers have heard of wearable fitness devices, only 28% buy them and a huge number of them stop using them hen they actually have them. how mainstream is this going to be, beth? >> well, hard to tell, we'll see what the market adopts. when you think of things like this, it's not used for a long enough period of time but a great statistic that i saw recently is over the past two years, people who were them walked 2.4 trillion steps. that's the equivalent of walking from here to saturn. so it's kind of remarkable. so people use them. what you need to do, i think measure reward. people respond when they have a reward at the end of it, so just seeing your steps or just seeing a measurement is not enough. you have to give people a prize.

give them an opportunity to be rewarded for what they're doing. >> scott, when you think about how widespread smart watches can potentially be, do you think it could become as big as a smartphone market or just it's never going to come close? >> i can't agree more with the latter of those two conclusions. the way we think about this is on one hand, as was just referenced, a lot of companies have introduced a lot of related products over the last couple of years. and to be frank, it seems like notwithstanding the enthusiasm, these offerings have not had sustainable success, i would argue, to a large extent. and it is kind of interesting that this is something that people can buy, and improve their lives, yet seemingly more people are interested in yo, the app, than these kinds of wearable devices. so, i think that people need to

maybe think about priorities, but in light of that, we think apple is going to have an uphill climb when it comes to this category. >> i am one of those people who these. t a lot of these i'm just not compeled to use it every day. of the bands that are out there. do you think apple is really going to significantly hurt the competition? >> i think there's going to be different options for different people. so, one of the problems with today's bands are the engagement. so if apple can find a way to have a two-way interaction with the watch, i think people will be more engaged and therefore will be more willing to use it. if it's a beautiful product, people will want to wear it. i don't wear them, not because i don't want to measure. i hate the way they look. >> right. and what we wear is such an

expression of who we are. we want them to actually look good. scott, what do you make of the report that they're working on multiple screen sizes? obviously that's very different than the iphone. still only one screen size. the ipad initially, there was only one size. if they are indeed working on multiple sizes, what does that tell us? >> yeah, i think that actually is kind of a surprising characterization of where apple is going this early in the process with regard to this particular category. we're frankly a little bit skeptical as to whether or not you're going to see right off the back, two separate or multiple separate kind of screen sizes and product offerings. i think frankly what it says perhaps is that apple is aware that as best indicated, different products are going to cater to different kinds of users and use cases. that being said, however, i do think while it's important that the product is beautiful, and it's kind of garners people's interest and attention, think about it also in the context

that people are going to be using this when they're working out so they need something rugged and something that will be able to hold up to sweat and other kind of tribulations. so we think the way this will play out isn't exactly how people might expect at this point. >> are there start-ups that are banking their futures on an i-watch that are sitting there well once apple comes out with something, we're going to go big. you're investing in a lot of these companies, right? are any of them waiting for this? >> i haven't heard that exactly spoken that way, but people are waiting for a broader platform to be able to expand the amount of things that they can measure. >> ok, you're with us for the hour. thank you, and scott kessler of s & p capital, thank you so much for joining us today. coming up, investing in bio tech and digital health, where are the opportunities. our guest host takes us through

where she sees big potential. and you can watch it streaming on your tablet, your phone.

>> microsoft describes its tablet as a tablet that will replace your laptop. it hits stores today with a starting price of $799 with a 12 inch screen. it is thinner and lighter than its predecessor. microsoft exceeds $376 million since the release of the original surface back in october 2012. we'll see if this one sells any better. and we are back with our special guest host for the hour, general partner at kleiner perkins call

field. no cusses on life sciences investing in a range of bio tech and digital health companies from finding a cure to cancer to developing mobile apps to help consumers manage their medication. so, how does investing in life sciences difference from technology companies? so we focus a lot on consumer and enterprise technology. how is health tech different? >> yeah, one of the main differences is it's very personal. and if you think about what people are doing with their information, whether it's to get healthier or to find out what their health is about, it's personal. a number of things we do is regulated. so, you know, you can't just go out and put out something that's going to tell you about your disease state or diagnose you without f.d.a. getting involved. >> is it harder or easier to

find the diamonds? is there more or less competition? is there more or less volume? >> there is a tremendous amount of volume. i can't process all of the opportunities that are coming our way, so we're very excited about the opportunities. there's less competition, but competition is heating up. we're seeing a lot of traditional, digital invests who are seeing the path and the pattern of opportunity. >> well, they've obviously put a big bet on life sciences. now, for a very long time what have been the returns compared to what you see? what makes it worth it for you guys? >> well, returns matter. our returns, particularly on bio tech and soon, we hope, on the digital health side will be equal to our digital return, so we're doing well. and what makes it worth it is we're making a difference, and the partnership is part of the fabric of who the partnership is, and what we care about. >> so, what are the most exciting trends in digital

health? what are you most excited about? >> well, i'm excited about trying to address the problem in front of us with the baby boomers. >> and why is that important? what's the problem? >> well, the problem is there's a lot of them, they're not very healthy, but they love technology. >> apparently for the next 15 years, 10,000 baby boomers will turn 65 every single day. >> yes. so happy birthday to all of those who turn 65 today. but if you look at the other statistic, there are three million new people who are joining medicare every year. and medicare is not projected to increase in the amount of spending. so, people are going to be more responsible for their health. and, in order to address that, we think that digital technology is going to make a big difference. when you look at the baby boomers, their internet trends and the amount they used, the time they spent on the internet

is equal to the me lynn yill generation. >> oh, really? >> it's shocking. i didn't know that. >> what digital things will help them? >> we talked about one, perhaps the watch. so baby boomers, but not quite over the edge yet to be in the medicare generation. and 68% of them measure their weight or their exercise oracleries in some way. so, if we can find engaging tools, so things like an iwatch, fit band, fit bit or things like my fitness pal which is one of our companies, there are over 80 million users. that's a consumer product. there have been over 100 million pounds lost. 30% of americans are obese. we have to fix that problem. >> what about the affordable care act and the electronic, the making of all health records electronic?

what kind of opportunities are you seeing there? is it working, what are the challenges? >> yes, so, it's a challenge anytime you introduce new technology into a field that has basically thought that the high tech was a fax machine. so, there's a big cultural shift in the physician provider area. the beauty of this is we're building the pipes, so that now over 80% of hospitals have electronic medical records. we're only at 50% in the outpatient setting, so we have a ways to go. but once we get there, then people will have access to their information. >> ok. bio tech, we know that evaluations are on the consumer tech side in the private market. the nasdaq bio tech index is up more than 50% in the last year, but took a deep dive in march. there's been talk about a bio tech bubble. what are your latest thoughts on the environment? >> yeah, we spoke about this

last time i was on this show. >> has anything changed? >> well, it was a scary ride. white knuckles. in the market, started to go down and i thought, i said to you there's no bio tech bubble, then thought i was going to have to eat my words. but i don't think so. i still don't think there's a bubble. if you look at what happened year to date, 33 i.p.o.'s, their overall up 28%. just this week, three great i.p.o.'s. pharmaceuticals, kite and there are more coming. so, there's still a lot of optimism, a lot of money to be made, because we are able to now come up with better treatments that are going to get approved. >> speaking of treatments we'll talk more about efforts to secure cancer in this show. i'm excited to see what progress s happening there. coming up, is amazon burying the

hatchet with a publisher? we'll be back with the latest in the book battle next.

>> welcome back. amazon bows to consumer pressure amid its ongoing battle with the publisher. it's making an exception to its book locking accepting orders for j.k. rowling's latest book "the silk worm." but 5,000 of the publisher's titles are still showing out of stock as amazon seeks a bigger cut in ebook prices. we turn now to a wire in the world series where we look at how tech is shaping the future of health care. if you hate going to the doctor,

there's an app for that. ground break technology that lets you diagnose from the comfort of your living room. here's a look at three of these companies. >> certain technological breakthroughs have a way of making our lifes seem more like science-fiction than reality. think about the first time you ever used a smartphone or saw somebody use microsoft x-box kinect. all of the sudden the future was happening right now. these giant leaps have already changed the way we work and communicate. the next step, if a few start-ups have anything to say about it, is how we take care of our bodies. we may soon be able to diagnose ourselves using tiny sensors and the come putting power that's already in our hands. one company is dopping a hand held sensor that you will hold

to your forehead to get your temperature, heart rate, blood oxygen level and other data points. the sensor will send all of that data via blue tooth to your smartphone which can share the data with you, or email it to your doctor. another company has developed a mobile accessory which turns your phone's camera into a sort of ear scope. put it in your kid's ear, send the video to your kid's doctor, and you may be able to get that ear infection diagnosis, and more importantly, that anti-biotic prescription without even leaving home. a third outfit has developed a smartphone based ultrasound machine. it costs less than $8,000. a standard ultrasound rig will run you well into the six figures. already, it's being used in in developing nations to provide more accurate diagnosis. there are some skep i thinks out there. medical devices are incredibly complicated they scream! in some cases, they may be

right. these products are works in progress, but the improvements seem to be inevitable. think about it this way. 10 years ago, we barely knew what a smartphone was, and now we're talking about driverless cars. if you look at the history of the future, one thing seems clear. it's happening faster. >> that was bloomberg business week's, beth, our guest host for the hour, what do you think of that stuff? >> it's awesome. it's just fantastic. i can't believe, actually, that the smartphone is so smart. so, i think we're going to see more and more of these kind of apps and technologies. and what i'm most excited about is the data, because if you think about it, we've never had this data before. in between hospital visits, in between physician visits, all of a sudden you're going to be informed and empowered, and it's going to be awesome. >> all right, who invests in health tech and life sciences

will be with us for the hour. coming up, buzzfeed, one of the fastest growing sites on the web. how they give that great viral content. you can also watch it on your tablet phone, bloomberg tv.com. >> 26 minutes past this hour. let's get you caught up to where stocks are traded as we speak. you see an equity across the board, s&p just off session highs. record highs, record highs. .01%.ins up ont the s&p 500 up over 1%. let's check out oil.

a little bit lower through the trading day, but if you check this out on the month, it's quite remarkable. we are heading for the best month since august of last year.

>> we focus on technology and the future of business. this week, the leaders of the ing world g and market convened to discuss the future of the industry at the creativity -- one of the hot topics at the event was how to capture the attention of the variety of age groups that are now active on social media. market makers stephanie rule attended the event and sat down and asking if buzzfeed is starting to attract an older audience. >> it's hard to think of our young audience is still growing quickly, but my gut feeling is

that year starting to see a little bit of a shift. really we look at it in the level of individual post. so if we do a post about parenting or something like that, we'll see it reach an older audience or people have kids. if we do a post about, you know, signs that you missed your senior year of high school rgs it will skew a younger audience. >> a last year to those traditional media icons want your intel, want your time, want to understand how your business works. could we see buzzfeed become part? you have a partnership with cnn, but could we see a part of these iconic, traditional media brands? >> there's an intense amount of interest of what we're doing. we hear from people, big media companies, we also feel from people at small start-up companies who are doing businesses. so it's definitely fun to have people watching what we're doing and appreciating what we're doing, and evaluating it. with something that a couple years ago, we weren't really on

anybody's radar, so it's a different moment for us, where we're able to operate and have influence over a larger industry or people see what we do. >> do you have a dream partner? >> a dream partner? >> like my wife? >> so nice! like we would love to work with! bloomberg! a dream partner. >> bloomberg is a great company. [laughter] i mean, we tend to take the approach of making content ourselves. we work with lots of brands to make content, and that's 100% of our revenue comes from branded content. so, we have a lot of partners who are marketers and major brand or 76 with the top 100 brands down. so we do a lot of those. on the content side, we feel like the social platforms are great partners, and it's less about, less about having

contractal agreements and more interests to make the news feed and content streams of all the social platforms by creating really great content that can be shared across the web. >> do you have a favorite buzzfeed list ever? >> yeah, there are's one about people that actually list which is my favorite. more laughing out loud sort of thing. >> one of my favorites. how do you find these extreme? people you can't believe exist, animals that look like monsters. how do you find the most extreme? >> part of it is having a team of people who are really, you know, live and breathe the web, and who meet in small groups and brain storm ideas. a lot of lists are product of an internal email list or people throwing ideas around, saying have you seen this? have you seen this? then having the data feedback of what people are sharing helps us understand what do people really love, if they're sharing

something a lot, why is that? maybe they're sharing it because there's corgis in it, maybe because it's tied to father's day. maybe xyz. let's test that, make another content that is just about corgis. one tied to a holiday and doesn't have other elements. then you get better and better understanding what touches people's heads and hearts and funny bones and how do we make things that people will get excited to share. >> buzzfeed c.e.o. with stephanie rule at the creativity festival. 42 people that you can't believe actually exist and it is pretty epic on buzzfeed. well, talk show host chelsea handler is headed to netflix. the streaming service signed a deal with her that will include five specials, in addition to a new talk show set to start in early 2016. handler's current late night show is ending its run on the e network later this deal.

for more on what the deal means -- so, john, why did chelsea make the switch? >> well, on some levels this is snot surprising to me. netflix is all about comedy, chelsea is hungry to try something interesting and new. we've already seen obviously as netflix as moved into the world of original shows, they brought back arrested development, did "orange is the new black" which is a big hit. one of the first things she'll do is a comedy special. "parks and recreation" and they're also going to team up on some documentaries which will be more on the funny side but netflix is all about documentaries. where i'm still a little unsure is we're talking about redefining the rules of a talk show. if you think about where netflix has avoided stuff, content so far, it's those things that are really tied to linear television. like they get asked are you

going to get into sports? and say, not really. also what's the value of a sporting event after everybody's watched it when you're an on demand player. so how do they avoid the topical issues that seem less relevant a week or a year afterwards but keep people interested in the chelsea handler talk show. >> i wonder, i know she's doing specials but also the talk show which may be tied to, you know, an actor's movie release or some sort of news. is that going to play as well on netflix? >> you know, the first name that came to mind actually when i saw this announcement was jerry seinfeld, who has had some success on another platform, crackle, which is owned by sony, with a show about comedians who get in vintage cars and they just talk. so it might be that she has to avoid talking about one specific movie, or you know those references to it's coming out tomorrow. but there's no reason why you wouldn't want to be going after

people who have a movie to pitch, because that's one of the great ways that talk shows exist, or you can go and get somebody because you want to get the publicity out there. those are some of the big issues they'll have to talk about. >> what do you think of netflix, beth? it was just a couple of years ago the stock was plummetting, people were questioning its future. >> i think it's a spectacular turnaround story, and it's amazing, and i love netflix. >> you watch a lot of stuff? >> oh my god, "house of cards," "homeland" and my big question ringing chuyis she b with her? >> john, do we know? >> she's not saying anything yet, but she does have a team, doesn't she? i think you might see that, we'll see. >> so beth, it sounds like you're going to watch. >> i am going to watch. i'm a fan. >> any other favorite comedians? >> love jerry seinfeld. love billie crystal.

>> it's interesting john, john oliver who used to be on "the daily show" recently went to hbo nemesis.like netflix's he's doing a weekly show, it's gotten mixed reviews, i personally love john oliver. what do you think of the two different directions they've gone in? >> yeah, look, i think there's a great opportunity for, in the shifting landscape of late night for hbo and netflix to have made the moves that they've made. again, in terms of the kind of stuff that ends up being discussed, i think you do have a big difference. john oliver can say to his audience, be sure to tune in on sunday to watch this. so, you know, will they be exploring the same kind of subjects? they don't really to begin with, so that probably won't be a big issue. john oliver would have to take a different spin, certainly if he was on an on-demand platform. i think a lot of people like that netflix has an incredible

global reach, which is why other comedians have already teamed up with them. >> all right, john, thank you. beth, stay with us. well, forgot to take your meds? there is an app for that. we look at how one start-up is helping patients stick to medical treatment plans, next.

>> streaming on your phone, your tablet and bloomberg.com. we turn back to our wiring the world series. this week we're looking at how tech is changing the future of health care. four out of five adults in the u.s. take a combination of prescription meds over the counter drugs and supplements according to the center for disease control, but how often are they taking it properly?

an app has been designed to help patients keep track of when they take pills and how medications could be interacting. hey just raised -- also with us, just led a big investment in mango house. you joined the board. >> yes. >> so what did you see? >> an opportunity to address the problem. 50% of people on medications don't comply. they just don't take their meds. if you look at the cost of chronic diseases and not taking your meds, it's in the hundreds of billions of dollars. so, it's an enormous problem. we see this as an opportunity to have a mobile platform that can engage people in a very interesting way. and jason is just a spectacular entrepreneur, who took his experience in mobile gaming and

moved it to health care. >> tell me about that because you used to work at zynga, you were really in the gaming community and then you integrated some gaming into it. >> yeah, we were run of the earliest mobile gaming companies. and it sounds crazy, but it's actually quite similar work. really, our focus is building products that consumers want to use every day for very long periods of time and we're really just applying that now to solving some of the most difficult problems. >> what are the most difficult problems. i know chronic disease is very much a focus. >> chronic disease is key. it represents about 75% of all u.s. health care, as you probably know. the real issue is with many of these conditions, they tend to have very deferred consequences. >> what conditions? >> hypertension, high cholesterol, diabetes. many conditions like that. patients are just not feeling the effects of this disease every day. we're building products that inspire them to start thinking about this part of their lives now. >> there are so many health and

wellness apps out there, beth. why does mango health stand out to you? >> a lot of it is taking the gaming experience and bringing it to health care. it's all about engagement. if we can make these apps fun and engaging and reward people, we're going to see a big uptake in adherence. and that's what jason's doing. we believe that it's really going to make a difference. great example? my mom. so jason knows, we get real time feedback from my mom. >> you have your mom on mango health? >> i have her on mango health and it's making a difference for her because she has multiple different meds she has to remember to take every day, and quite frankly, she loves the rewards. target points, and other things that she can earn by being compliant is really moat visitinging. >> let's talk about engame. what sort of stats are you seeing? i did read somewhere that initially like the first month you see a lot of engagement,

then some people drop off, which is the same problem you're seeing with some of these health devices and wrist bands. >> well, you see for us the key thing to track initially is use overtime. so what we tend to see is 90 days into our program, we see about 67% of our audience still in the app regularly, which is about three times higher than what typically is seen in medication and health apps. so we're very pleased with that. equally important is levels of medication in our population. so we tend to see a lift of about 25%-30% in levels of adherence, which translates directly to lower cost of care overtime. >> we were talking about the iwatch earlier, the potential for apple to come out with something. is that exciting to you? is that competition because they have their own health app? >> we're really happy that the category is growing. i think what we're focused on is building with daily health management with supplement management because the truth is for millions of consumers,

better health starts there. that's really been our focus. >> i want to ask you more about beth, because you know, we focus on consumer and tech where there's so much competition, so many different venture can't lists out there and beth seems to be more in a league of her own, really. is that the case when it comes to life sciences and health tech? >> i certainly feel that way. we're an interesting company because we sit right at the intersection of consumer tech. and enterprise health care. there are very few firms that understand the intersections of those two things. kleiner perkins and beth happen to be one of them. they just have a very unique perspective. even very health care oriented investor typically don't understand the space we're in because it's historically being an operational problem, not really an investment category. there are huge dollars to be shaved here, so we're just so pleased we've had a firm like kleiner that has this expertise. >> beth, how do all of you keep

the different kinds of investments you're making all moving in the same direction, one coherent strategy? >> yeah, well, one of the things is we work as a team, and so, i'll sit down and with jason, for example, one of our partners ben gordon who runs our product and design work and work with jason. he's in there working with jason on prada, and john, who was on your show is working on design. we have mike abbott who ran all of the engineers at twitter who is helping jason scale his organization. so it's really a team effort and they say it takes a village, it takes a village to make a difference in health care. >> all right. our guest host for the hour, jason, we'll keep our eye on you guys, thank you so much for joining us. >> thank you. >> well, how could mapping technology help doctors treat cancer? we look at how medical researchers are using tech to hunt for a cancer cure next on

bloomberg west. you can watch us streaming on your phone, block berg.com, apple tv and amazon fire tv.

>> welcome back to bloomberg west. have a number today, what have you got? >> i got it 1.7 million. >> what's that? >> that's the number of people in the united states that were diagnosed with cancer in 2013. >> so you actually do a lot of work looking into companies that are trying to cure cancer and progress in cancer treatments. what kind of progress is there?

>> we're making major, major strides. probably the two areas, one is we now have technology based on the human gentlemen nome project here we can map a cancer gene. you can take an individual patient's tumor, map it, see what genes are there, then provide the list of the appropriate drugs or therapies that are going to be effective for that individual tumor. company that we invested in called foundation medicine is doing this work today and we're seeing major prucks. for example, the national cancer institute just lost a project for lung cancer, where using the foundation tests, multiple different other drugs to figure out a cure for lung cancer. >> you're also looking at how to regulate the immune system. >> yeah. >> to fight cancer. how does that work? >> it's called immune therapy.

different ways to do it. one, there's a product on the arket which basically is for melanoma. in that case it uses an anti-body to regulate the t-cells that will kill the cancer cells. so it's drugs regulating the t-cells. another type of therapy is actually taking an individual patient's t-cells, removing them rom the body, that's a type of lymphocite, using a car, t-cells, and then putting a virus into those cells. takes about 10 days to go through that process. you take the patients own t-cells, put them back into the body and they become smart bombs. because of the recentor they have, this is shown in a lot of patients with leukemia, they can go in, hone in to where the cancer cell is. they're like a trojan horse.

they go in, they invade the cell, they kill the cancer cell. they replicate themselves because they take over the reply cation process in the cell and they go off and do it again. spectacular results are being seen. >> you hear a lot about this unicorn, someday cancer will be cured. there are so many different kinds of cancers, they act in so many different ways. is the cure for cancer going to be incremental, or if done today, boom, cancer will be cured. >> it won't be a boom. but it won't be a bust, because we have technology that, by being able to map the genome of a cancer. for example, now, we will have the knowledge to know what treatments to give. so, i think it's going to be a cancer at a time, but like h.i.v. and like many other illnesses that we've seen in our lifetime, it become a chronic disease. i believe that will happen in my lifetime, and i believe we're seeing such dramatic changes

that we're at the beginning of that journey. >> so you're saying within decades? >> oh yeah, i am absolutely confident within decades we'll see certain cancers that will be, you're calling it cured, but basically kept in check, so that it becomes chronic, and not -- people won't die from that illness. they'll die from something else. >> and one last question, regulatory issues, in the f.d.a., you know, does that make your job a lot more difficult? >> it makes it interesting. >> yeah. >> because we need to understand the regulations. but f.d.a., for example, in cancer, they've helped make the breakthrough because of breakthrough therapy designation. so, interesting times. >> thanks so much for joining us today. our guest host for the hour, it's been great to have you. and thank you all for watching this edition of "bloomberg west." it is friday, have a wonderful

weekend.

flume bloomberg world headquarters in new york, this is bottom line. what is next for iraq? we have an exclusive bloomberg interview from towns, france. france.s, to our viewers here in the united states and around the world, welcome peewee of full coverage of the stocks and stories making headlines today.